Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
| ▸ | PRKCB | P05771 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | PRKCH | P24723 | 1/20 | 0.30 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039964 | 0.92 | LMNA (0.34) | TBK1IDO1TDO2IDO2NR1H2 | |
| SCHEMBL3040294 | 0.92 | SOS1 (0.34) | TBK1IDO1TDO2IDO2NR1H2 | |
| SCHEMBL3046630 | 0.91 | IDO1 (0.35) | TBK1IDO1TDO2IDO2NR1H2 | |
| SCHEMBL3047031 | 0.90 | NR1H2 (0.39) | NR1H2NR1H3 | |
| SCHEMBL3042102 | 0.90 | LMNA (0.34) | TBK1NR1H2 | |
| SCHEMBL3047986 | 0.89 | HTR6 (0.37) | TBK1NR1H2NR1H3 | |
| SCHEMBL3040219 | 0.89 | NR1H2 (0.34) | NR1H2NR1H3 | |
| SCHEMBL3048077 | 0.89 | NR1H2 (0.34) | TBK1NR1H2NR1H3 | |
| SCHEMBL3046639 | 0.89 | NR1H2 (0.35) | TBK1NR1H2NR1H3 | |
| SCHEMBL3043784 | 0.88 | BDKRB1 (0.34) | TBK1HRH3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | TBK1 3936/4885HRH3 229/4885IDO1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.